Ruthenium(II) and Iridium(III) Complexes as Tested Materials for New Anticancer Agents

The oncological use of cisplatin is hindered by its severe side effects and a very important resistance problem. To overcome these problems, scientists have attempted to design new generation transition-metal anticancer complexes. In this study, we present new complexes, ruthenium(II) [(η(6)-p-cymen...

Descripción completa

Detalles Bibliográficos
Autores principales: Masternak, Joanna, Gilewska, Agnieszka, Barszcz, Barbara, Łakomska, Iwona, Kazimierczuk, Katarzyna, Sitkowski, Jerzy, Wietrzyk, Joanna, Kamecka, Anna, Milczarek, Magdalena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7475896/
https://www.ncbi.nlm.nih.gov/pubmed/32784666
http://dx.doi.org/10.3390/ma13163491

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7475896/
https://www.ncbi.nlm.nih.gov/pubmed/32784666
http://dx.doi.org/10.3390/ma13163491

Ejemplares similares